Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Kim N. Chi, Noel Clarke, Ian D. Davis, Johann de Bono, Charles G. Drake, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim FizaziMark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Daniel Heinrich, Celestia (Tia) S. Higano, Michael S. Hofman, Maha Hussain, Nicolas James, Ravindran Kanesvaran, Philip Kantoff, Raja B. Khauli, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Robert E. Reiter, Mack Roach, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Eric Small, Matthew Smith, Howard Soule, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary Ellen Taplin, Bertrand Tombal, Levent Türkeri, Inge van Oort, Almudena Zapatero, Aurelius Omlin

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.

Original languageEnglish (US)
Pages (from-to)508-547
Number of pages40
JournalEuropean Urology
Issue number4
StatePublished - Apr 2020

Bibliographical note

Funding Information:
Although there was a range of opinions regarding the starting dose of chemotherapy in patients of East Asian ethnicity, 60% of panellists recommended starting chemotherapy at a reduced dose. This strategy is supported by the experience of physicians from the Asia-Pacific region and by limited studies. Although no large prospective clinical trials have compared dosing strategies (eg, a reduced dose vs a full dose with G-CSF support) in this population, the available literature suggests that antitumour activity is comparable, even if a reduced dose is used [174,175] .

Funding Information:
Funding/Support and role of the sponsor: We gratefully acknowledge the following organisations for providing financial support for the APCCC 2019: Canton of Basel, European School of Oncology (ESO), Swiss Cancer League, Swiss Oncology Research Network (SAKK), Prostate Cancer Foundation (PCF), and Cantonal Hospital St. Gallen. We would like to especially thank the Movember Foundation for generously supporting the APCCC 2019. Special thanks also to the EAU, the European Organisation for Research and Treatment of Cancer (EORTC), the European Society for Radiotherapy and Oncology (ESTRO), and the European School of Oncology (ESO) for their endorsements. We also acknowledge sponsorship from several for-profit organisations, including Astellas, Bayer Health Care, AstraZeneca, MSD, Pfizer Oncology, Janssen Oncology, Sanofi Genzyme, Amgen, Clovis Oncology, Ferring Pharmaceuticals, Ipsen, Roche, Tolmar, Advanced Accelerator Applications, and Orion Pharma (details on sponsorship are available at ). These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication. Ian D. Davis is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1102604). Michael S. Hofman is supported by a clinical fellowship award from the Peter MacCallum Foundation.


  • Advanced prostate cancer
  • Castration-naïve prostate cancer
  • Castration-resistant prostate cancer
  • Genetics
  • High-risk localised prostate cancer
  • Hormone-sensitive prostate cancer
  • Imaging
  • Oligometastatic prostate cancer
  • Overall survival
  • Progression-free survival
  • Prostate cancer treatment
  • Tumour genomic profiling

Fingerprint Dive into the research topics of 'Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]'. Together they form a unique fingerprint.

Cite this